AR095496A1 - Formulaciones de anticuerpos anti-receptor de prolactina - Google Patents
Formulaciones de anticuerpos anti-receptor de prolactinaInfo
- Publication number
- AR095496A1 AR095496A1 ARP140101101A ARP140101101A AR095496A1 AR 095496 A1 AR095496 A1 AR 095496A1 AR P140101101 A ARP140101101 A AR P140101101A AR P140101101 A ARP140101101 A AR P140101101A AR 095496 A1 AR095496 A1 AR 095496A1
- Authority
- AR
- Argentina
- Prior art keywords
- prolactin
- formulations
- receiver
- antibodies anti
- prlr antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361799629P | 2013-03-15 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR095496A1 true AR095496A1 (es) | 2015-10-21 |
Family
ID=50678293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140101101A AR095496A1 (es) | 2013-03-15 | 2014-03-14 | Formulaciones de anticuerpos anti-receptor de prolactina |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9023357B2 (https=) |
| EP (1) | EP2968538A1 (https=) |
| JP (1) | JP2016515515A (https=) |
| CN (1) | CN105025925A (https=) |
| AR (1) | AR095496A1 (https=) |
| CA (1) | CA2906101A1 (https=) |
| HK (1) | HK1215175A1 (https=) |
| TW (1) | TW201513882A (https=) |
| UY (1) | UY35460A (https=) |
| WO (1) | WO2014143909A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX361875B (es) | 2012-03-14 | 2018-12-18 | Regeneron Pharma | Moléculas de unión de antígeno multiespecifícas y usos de las mismas. |
| EP2968538A1 (en) * | 2013-03-15 | 2016-01-20 | Bayer HealthCare LLC | Anti-prolactin receptor antibody formulations |
| TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗－ｐｒｌｒ抗體及其用途 |
| US9545451B2 (en) | 2013-08-21 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Anti-PRLR antibodies and methods for killing PRLR-expressing cells |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| MY189159A (en) | 2015-07-06 | 2022-01-29 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
| MX2018007520A (es) | 2015-12-18 | 2018-08-01 | Astellas Pharma Inc | Composicion farmaceutica que comprende un anticuerpo receptor de linfopoyetina estromal timica antihumano. |
| IL249795B (en) | 2016-02-05 | 2020-01-30 | Grifols Worldwide Operations Ltd | Intradermal administration of an immunoglobulin preparation g |
| WO2017190079A1 (en) | 2016-04-28 | 2017-11-02 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
| CA3038894A1 (en) | 2016-09-28 | 2018-04-05 | Board Of Regents, The University Of Texas System | Antibody and protein therapeutic formulations and uses thereof |
| WO2018102304A1 (en) | 2016-11-29 | 2018-06-07 | Regeneron Pharmaceuticals, Inc. | Methods of treating prlr positive breast cancer |
| KR20180106974A (ko) * | 2017-03-16 | 2018-10-01 | 주식회사 엘지화학 | 항-tnf 알파 항체의 액상 제제 |
| TW201836647A (zh) | 2017-04-06 | 2018-10-16 | 美商艾伯維有限公司 | 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途 |
| JP7297672B2 (ja) | 2017-04-13 | 2023-06-26 | アジェナス インコーポレイテッド | 抗ｃｄ１３７抗体およびその使用方法 |
| BR112020015016A2 (pt) | 2018-01-26 | 2020-12-29 | Genentech, Inc. | Composições farmacêuticas, métodos de tratamento da doença inflamatória intestinal, de inibição da infecção microbiana no intestino e de aceleração ou melhora da cicatrização de feridas |
| JP7779653B2 (ja) | 2018-02-07 | 2025-12-03 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 治療用タンパク質送達のための方法および組成物 |
| KR102735988B1 (ko) | 2019-02-18 | 2024-12-03 | 일라이 릴리 앤드 캄파니 | 치료 항체 제제 |
| KR20250120995A (ko) | 2022-11-07 | 2025-08-11 | 업스트림 바이오, 인크. | 항-인간 tslp 수용체 항체를 포함하는 약제학적 조성물 및 이를 사용하는 방법 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| AU2003293543A1 (en) * | 2002-12-13 | 2004-07-09 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| AR062435A1 (es) * | 2006-08-18 | 2008-11-05 | Xoma Technology Ltd | Anticuerpo especifico prlr (receptor de prolactina) y sus usos |
| KR101456728B1 (ko) * | 2006-09-08 | 2014-10-31 | 메디뮨 엘엘씨 | 인간화 항-ｃｄ19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도 |
| JP2010512356A (ja) * | 2006-12-11 | 2010-04-22 | エフ．ホフマン−ラ ロシュ アーゲー | 非経口ａベータ抗体製剤 |
| US20100189723A1 (en) * | 2007-01-11 | 2010-07-29 | Peter Andreas Nicolai Reumert Wagtmann | Anti-kir antibodies, formulations, and uses thereof |
| RU2010120674A (ru) * | 2007-10-22 | 2011-11-27 | Шеринг Корпорейшн (US) | Полностью человеческие анти-vegf-антитела и способы их применения |
| PE20110302A1 (es) | 2008-09-19 | 2011-05-21 | Hoffmann La Roche | Formulacion farmaceutica de un anticuerpo contra p-selectina |
| EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| MX2011011772A (es) * | 2009-05-04 | 2012-02-08 | Abbott Biotech Ltd | Formulaicones estables de anticuerpos humanos anti-tnf-alfa con alta concentracion de proteina. |
| EP2332995A1 (en) * | 2009-12-10 | 2011-06-15 | Bayer Schering Pharma Aktiengesellschaft | Neutralizing prolactin receptor antibodies and their therapeutic use |
| MX2012007676A (es) | 2009-12-29 | 2012-08-03 | Hoffmann La Roche | Nueva formulacion de anticuerpo. |
| US20110223208A1 (en) * | 2010-03-09 | 2011-09-15 | Beth Hill | Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations |
| US8883979B2 (en) * | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| EP2968538A1 (en) * | 2013-03-15 | 2016-01-20 | Bayer HealthCare LLC | Anti-prolactin receptor antibody formulations |
-
2014
- 2014-03-14 EP EP14722033.9A patent/EP2968538A1/en not_active Withdrawn
- 2014-03-14 JP JP2016502699A patent/JP2016515515A/ja active Pending
- 2014-03-14 WO PCT/US2014/028078 patent/WO2014143909A1/en not_active Ceased
- 2014-03-14 TW TW103109457A patent/TW201513882A/zh unknown
- 2014-03-14 HK HK16103172.6A patent/HK1215175A1/zh unknown
- 2014-03-14 AR ARP140101101A patent/AR095496A1/es unknown
- 2014-03-14 CA CA2906101A patent/CA2906101A1/en not_active Abandoned
- 2014-03-14 CN CN201480016050.7A patent/CN105025925A/zh active Pending
- 2014-03-14 UY UY0001035460A patent/UY35460A/es not_active Application Discontinuation
- 2014-03-14 US US14/213,497 patent/US9023357B2/en active Active
- 2014-03-14 US US14/772,369 patent/US20160002342A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HK1215175A1 (zh) | 2016-08-19 |
| CN105025925A (zh) | 2015-11-04 |
| US20160002342A1 (en) | 2016-01-07 |
| US20140271659A1 (en) | 2014-09-18 |
| EP2968538A1 (en) | 2016-01-20 |
| TW201513882A (zh) | 2015-04-16 |
| US9023357B2 (en) | 2015-05-05 |
| UY35460A (es) | 2014-10-31 |
| WO2014143909A1 (en) | 2014-09-18 |
| JP2016515515A (ja) | 2016-05-30 |
| CA2906101A1 (en) | 2014-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR095496A1 (es) | Formulaciones de anticuerpos anti-receptor de prolactina | |
| AR092401A1 (es) | Formulaciones de anticuerpos anti-receptor de prolactina (anti-prlr) | |
| AR130402A2 (es) | Formulaciones de anticuerpos anti-pdl1 | |
| MX363380B (es) | Formulacion de anticuerpos. | |
| PE20181400A1 (es) | Formulacion farmaceutica acuosa del anticuerpo anti-pd-l1 avelumab | |
| HRP20191299T1 (hr) | Formulacije protutijela | |
| AR108240A1 (es) | Formulaciones que contienen anticuerpos | |
| PE20170780A1 (es) | Formulacion estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf | |
| ES2676205T3 (es) | Formulaciones estables de anticuerpos para el receptor PD-1 humano de muerte programada y tratamientos relacionados | |
| CL2019002190A1 (es) | Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984) | |
| PE20190405A1 (es) | FORMULACION PARA ANTICUERPO ANTI-alfa4beta7 | |
| MX385109B (es) | Formulaciones de anticuerpos. | |
| RU2013148119A (ru) | Лиофилизированный препарат ботулотоксина | |
| PE20142407A1 (es) | Formulacion de anticuerpos | |
| BR112016008576A2 (pt) | Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária | |
| SV2018005621A (es) | Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h | |
| EA201490804A1 (ru) | Препараты этанерцепта, стабилизированные хлоридом натрия | |
| NZ627859A (en) | Stabilized formulations containing anti-ang2 antibodies | |
| AR098168A1 (es) | Formulación estable de insulina glulisina | |
| EA201370178A1 (ru) | Стабильные составы для парентеральной инъекции пептидных лекарственных средств | |
| PE20160012A1 (es) | Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral | |
| PE20142167A1 (es) | Anticuerpos anti-lgr5 e inmunoconjugados | |
| AR095396A1 (es) | Formulaciones de anticuerpo | |
| GT201500046A (es) | Mètodos para el tratamiento de infecciones de hepatitis b y hepatitis d | |
| PE20151524A1 (es) | FORMULACIONES DE LA SOLUCION DE LOS ANTICUERPOS ANTI-IL-23p19 MANIPULADOS GENETICAMENTE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |